OBJECTIVES: The objective of this study was to investigate the efficiency of uptake of PEGylated polylactide-co-gycolide (PLGA) nanoparticles by breast cancer cells. METHODS: Nanoparticles of PLGA containing various amounts of polyethylene glycol (PEG, 5%-15%) were prepared using a double emulsion solvent evaporation method. The nanoparticles were loaded with coumarin-6 (C6) as a fluorescence marker. The particles were characterized for surface morphology, particle size, zeta potential, and for cellular uptake by 4T1 murine breast cancer cells. KEY FINDINGS: Irrespective of the amount of PEG, all formulations yielded smooth spherical particles. However, a comparison of the particle size of various formulations showed bimodal distribution of particles. Each formulation was later passed through a 1.2 µm filter to obtain target size particles (114-335 nm) with zeta potentials ranging from -2.8 mV to -26.2 mV. While PLGA-PEG di-block (15% PEG) formulation showed significantly higher 4T1 cellular uptake than all other formulations, there was no statistical difference in cellular uptake among PLGA, PLGA-PEG-PLGA tri-block (10% PEG), PLGA-PEG di-block (5% PEG) and PLGA-PEG di-block (10% PEG) nanoparticles. CONCLUSION: These preliminary findings indicated that the nanoparticle formulation prepared with 15% PEGylated PLGA showed maximum cellular uptake due to it having the smallest particle size and lowest zeta potential.
OBJECTIVES: The objective of this study was to investigate the efficiency of uptake of PEGylated polylactide-co-gycolide (PLGA) nanoparticles by breast cancer cells. METHODS: Nanoparticles of PLGA containing various amounts of polyethylene glycol (PEG, 5%-15%) were prepared using a double emulsion solvent evaporation method. The nanoparticles were loaded with coumarin-6 (C6) as a fluorescence marker. The particles were characterized for surface morphology, particle size, zeta potential, and for cellular uptake by 4T1murinebreast cancer cells. KEY FINDINGS: Irrespective of the amount of PEG, all formulations yielded smooth spherical particles. However, a comparison of the particle size of various formulations showed bimodal distribution of particles. Each formulation was later passed through a 1.2 µm filter to obtain target size particles (114-335 nm) with zeta potentials ranging from -2.8 mV to -26.2 mV. While PLGA-PEG di-block (15% PEG) formulation showed significantly higher 4T1 cellular uptake than all other formulations, there was no statistical difference in cellular uptake among PLGA, PLGA-PEG-PLGA tri-block (10% PEG), PLGA-PEG di-block (5% PEG) and PLGA-PEG di-block (10% PEG) nanoparticles. CONCLUSION: These preliminary findings indicated that the nanoparticle formulation prepared with 15% PEGylated PLGA showed maximum cellular uptake due to it having the smallest particle size and lowest zeta potential.
Authors: Richard A Graves; Sarala Pamujula; Raisa Moiseyev; Thomas Freeman; Levon A Bostanian; Tarun K Mandal Journal: Int J Pharm Date: 2004-02-11 Impact factor: 5.875
Authors: S Stolnik; S E Dunn; M C Garnett; M C Davies; A G Coombes; D C Taylor; M P Irving; S C Purkiss; T F Tadros; S S Davis Journal: Pharm Res Date: 1994-12 Impact factor: 4.200
Authors: Elizabeth A Nance; Graeme F Woodworth; Kurt A Sailor; Ting-Yu Shih; Qingguo Xu; Ganesh Swaminathan; Dennis Xiang; Charles Eberhart; Justin Hanes Journal: Sci Transl Med Date: 2012-08-29 Impact factor: 17.956
Authors: Jung Soo Suk; Anthony J Kim; Kanika Trehan; Craig S Schneider; Liudmila Cebotaru; Owen M Woodward; Nicholas J Boylan; Michael P Boyle; Samuel K Lai; William B Guggino; Justin Hanes Journal: J Control Release Date: 2014-01-14 Impact factor: 9.776
Authors: Panagiotis Mastorakos; Siva P Kambhampati; Manoj K Mishra; Tony Wu; Eric Song; Justin Hanes; Rangaramanujam M Kannan Journal: Nanoscale Date: 2015-03-07 Impact factor: 7.790